Category Archives: Infringement

DC decision of infringement and no invalidity of Pharmacyclic’s BTK inhibitor-related patents affirmed

Pharmacyclics LLC, Jannsen Biotech, Inc. v. Alvogen, Inc., Natco Pharma Limited Docket No. 2021-2270 (https://cafc.uscourts.gov/opinions-orders/21-2270.OPINION.11-15-2022_2033497.pdf) (Non-Precedential) CHEN, BRYSON, HUGHES November 15, 2022 Brief Summary:   DC decisions that Pharmacyclic’s patents were infringed and not invalid for lack of written description, … Continue reading

Posted in Anticipation (35 USC 102), Double Patenting, Enablement, Generics / ANDA, Incorporation by Reference, Infringement, Method claims, Obviousness, Obviousness (Secondary Considerations), Priority, Public Accessibility, Written description | Leave a comment

DC decision of no infringement by Eagle’s ANDA specification and denial of DJ affirmed

Par Pharmaceutical, Inc. et al. v. Eagle Pharmceuticals, Inc. Docket No. 2021-2342 (https://cafc.uscourts.gov/opinions-orders/21-2342.OPINION.8-18-2022_1993064.pdf) MOORE, PROST, HUGHES August 18, 2022 Brief Summary:   DC finding of no infringement under 271(e)(2) affirmed based on Eagle’s ANDA specification to which Eagle is bound, … Continue reading

Posted in Claim Construction, Generics / ANDA, Infringement, Method claims, Safe Harbor, FDA exemptions (271(e)(1)) | Leave a comment

DC denial of Thales’ motion to enjoin Philips’ ITC exclusion order as Thales did not show it was likely to suffer irreparable harm affirmed

Koninklijke Philips N.V. et al. v. Thales DIS AIS USA LLC, et al. Docket No. 2021-2106 (https://cafc.uscourts.gov/opinions-orders/21-2106.OPINION.7-13-2022_1977322.pdf) MOORE, DYK, CHEN July 13, 2022 Brief Summary:   DC denial of Thales motion to enjoin Philips from seeking ITC exclusion order affirmed … Continue reading

Posted in Infringement, International Trade Commission, Software | Leave a comment

DC indefiniteness conclusion vacated for incorrect claim construction, grant of SJ regarding jurisdiction vacated

Univ. of Massachusetts, Carmel Labs., LLC v. L’Oreal S.A. and L’Oreal USA, Inc. Docket No. 2020-1969 (https://cafc.uscourts.gov/opinions-orders/21-1969.OPINION.6-13-2022_1964183.pdf) PROST, MAYER, TARANTO June 13, 2022 Brief Summary:   DC indefiniteness finding vacated due to improper claim construction and grant of SJ for … Continue reading

Posted in Claim Construction, Claim Differentiation, Infringement, Inter Parties Review (IPR), IPR, Prosecution History Estoppel, Wherein, Written description | Leave a comment

DC denial of on-sale bar defense reversed; claim construction affirmed; grant of enhanced damages reversed based on attorney opinion; reasonably royalty affirmed

Sunoco Partners Marketing & Terminals, L.P. v. U.S. Venture, Inc. et al. (“Venture”) Docket No. 2020-1640, -1641 (https://cafc.uscourts.gov/opinions-orders/20-1640.OPINION.4-29-2022_1943607.pdf) PROST, REYNA, STOLL April 29, 2022 Brief Summary:  DC denial of on-sale bar defense reversed; claim construction affirmed; grant of enhanced damages … Continue reading

Posted in Claim Construction, Claim Differentiation, Damages, Experimental Use, Expert Testimony, Infringement, Lost Profits, On-Sale Bar, Royalties, Willfullness | Leave a comment

DC grant of SJ reversed and remanded due to improper finding of indefiniteness

Niazi Licensing Corporation v. St. Jude Medical S.C., Inc. Docket No. 2021-1864 (https://cafc.uscourts.gov/opinions-orders/21-1864.OPINION.4-11-2022_1934126.pdf) TARANTO, BRYSON, STOLL April 11, 2022 Brief Summary:   DC findings of indefiniteness reversed, but induced infringement, exclusion of expert witness report and damages findings affirmed. Summary:  … Continue reading

Posted in Claim Construction, Claim Differentiation, Damages, Expert Testimony, Indefiniteness, Inducement to Infringe, Infringement, Medical Devices, Method claims, Prosecution History Estoppel, Royalties, Written description | Leave a comment

DC decisions of induced infringement of patent asserted by Meso and non-infringement of non-asserted patents as requested by Roche vacated and remanded

Roche Diagnostics Corp., Bioveris Corp. v. Meso Scale Diagnostics, LLC Docket No. 2021-1609, -1633 (https://cafc.uscourts.gov/opinions-orders/21-1609.OPINION.4-8-2022_1933410.pdf) NEWMAN (D), PROST, TARANTO April 8, 2022 Brief Summary:   DC findings of induced infringement of patents asserted by Meso and non-infringement of non-asserted patents … Continue reading

Posted in Assignment / Ownership, Damages, Inducement to Infringe, Infringement, Licensing | Leave a comment

DC reversed on WD of genus claims and patent co-ownership, affirmed on no willfulness and remanded for damages calculation

BASF Plant Science, L.P., Cargill, Inc. v. Commonwealth Scientific, et al. (“CSIRO”) Docket No. 2020-1415-16, 2020-1919-20 (https://cafc.uscourts.gov/opinions-orders/20-1415.OPINION.3-15-2022_1921729.pdf) NEWMNA (D), TARANTO, CHEN March 15, 2022 Brief Summary:   Following a dispute regarding a collaboration agreement, FC panel affirmed DC fining on … Continue reading

Posted in Assignment / Ownership, Infringement, Inventorship, Licensing, Royalties, Venue, Willfullness, Written description | Leave a comment

DC finding that Polymetrix did not induce importation of samples into the US affirmed

Alpek Polyester, S.A., DAK Americas LLC, et al. v. Polymetrix AG Docket No. 2021-1706 (https://cafc.uscourts.gov/opinions-orders/21-1706.OPINION.12-16-2021_1880727.pdf) (Non-precedential) LOURIE, O’MALLEY, STOLL December 16, 2021 Brief Summary:  DC grant of SJ of no induced infringement by importation affirmed. Summary:  Alpek/DAK appealed DC grant … Continue reading

Posted in Importation, Inducement to Infringe, Infringement, Licensing | Leave a comment

DC Hatch-Waxman decision finding improper venue and failure to state a claim affirmed

Celgene Corp. v. Mylan Pharmaceuticals Inc., et al. Docket No. 2021-1154 (https://cafc.uscourts.gov/opinions-orders/21-1154.OPINION.11-5-2021_1860406.pdf) PROST, CHEN, HUGHES November 5, 2021 Brief Summary:  DC finding of improper venue and failure to state a claim affirmed. Summary:  Celgene sued Mylan for infringement under the … Continue reading

Posted in Generics / ANDA, Infringement, Jurisdiction, Venue | Leave a comment